Diasorin S.p.a. · MIL:DIA
Diasorin — Merger or Acquisition (March 2010)
19 slides from Diasorin's merger presentation, March 2010
Slide 1: MUREX Acquisition
DiaSorin DiaSorin MUREX Acquisition The Diagnostic Specialist
Slide 2: Disclaimer
Disclaimer Save where otherwise indicated, the Company is the source of the content of this Presentation. Care has been taken to ensure that the facts stated in this Presentation are accurate, and that the opinions expressed are fair and reasonable. However, no representation or warranty, express or
Slide 3: Strategic Guidelines: 5 Main Growth Drivers
Strategic Guidelines: 5 Main Growth Drivers ●Development of new assays (menu expansion), including HIV and HCV ●Development of a new proprietary testing platform (LIAISON XL) ●Development of new assay technologies, including molecular diagnostics research GROWTH (new IVD segment) ●Geographical expan
Slide 4: New assays and new platform (Liaison XL)
New assays and new platform (Liaison XL) Strengthening of New Markets with New Test s available Keep exploring specialty assays Infectious Disease and only on the New Liaison XL platform markets Endocrinology panel Chlamidia Chlamidia Parvovirus Anti HBs 2.0 Trachomatis Pneumoniae HIV Combo Measles
Slide 5: Further steps in geographical expansion
Further steps in geographical expansion Mexico Portugal Canada China Israel Austria China Czech Republic Australia Ireland 2005-2007 2008 2009 2010 The Diagnostic Specialist March 2010 4
Slide 6: Murex is Abbott arm in HIV and Hepatitis blood screening
“Murex is Abbott arm in HIV and Hepatitis blood screening testing outside Europe, US and Japan where ELISA still plays a role.”
Slide 7: Murex Assets acquired by DiaSorin
Murex Assets acquired by DiaSorin ●Two manufacturing sites, Dartford in UK and Kyalami in SA, employing less than 250 people. ●The use of MUREX Brand. ●All the raw material currently used by Abbott to make the EIA products for HIV, HCV and HBV. ●All relevant IP (either transferred or licensed) neces
Slide 8: Murex 2009 sales by Geographical Area
Murex 2009 sales by Geographical Area Europe APAC 25,9% 27,5% South America 46,6% The Diagnostic Specialist March 2010 7
Slide 9: Murex 2009 sales by Product line
Murex 2009 sales by Product line HCV 34,0% Other 9,2% HIV 21,3% HTLV 19,7% HBV 15,8% The Diagnostic Specialist March 2010 8
Slide 10: Blood Screening Market
Blood Screening Market ● In most countries it is mandatory to test the blood supply for HIV, HCV, HBV e Siphilis before transfusion. ● In some countries, two more tests are also mandatory: HTLV I/II and Chagas. ● In EU, US and Japan political pressure has forced blood banks to adopt NAT testing alon
Slide 11: HIV/Hep are used for Blood Screening and Diagnostic testing
HIV/Hep are used for Blood Screening and Diagnostic testing Blood bank represents more than half of testing VOLUME….. Diagnostic 40,0% Blood Bank 60,0% The Diagnostic Specialist March 2010 10
Slide 12: HIV/Hep are used for Blood Screening and Diagnostic testing
HIV/Hep are used for Blood Screening and Diagnostic testing …. but Diagnostic use represents 60% of the market due to PRICE Diagnostic 60,0% Blood Bank 40,0% The Diagnostic Specialist March 2010 11
Slide 13: Abbott dominates the Hepatitis market
Abbott dominates the Hepatitis market > 500 MM Euro Source: Company data The Diagnostic Specialist March 2010 12
Slide 14: Abbott dominates the HIV market
Abbott dominates the HIV market > 280 Mm € Source: Company data The Diagnostic Specialist March 2010 13
Slide 15: Europe HEP/HIV Market by Technology
Europe HEP/HIV Market by Technology ELISA share is small and fragmented among few suppliers Revenues by technology Market Share - EIA MM Euro Tot: 440 MM Euro 20% 30% 20% Others 30% J&J Siemens EIA-open systems Biorad CLIA-closed systems Source: Company data The Diagnostic Specialist March 2010 14
Slide 16: Hep/HIV Market EIA Pacific (ex. Jap)/S.Am.
Hep/HIV Market EIA Pacific (ex. Jap)/S.Am. 2009 Fragmented market with few unfocused players APAC/South Am. Hep/HIV EIA Market 2009 Market Share MM Euro Tot: 150 MM Euro HCV Biomerieux HIV Biorad HAV; HBV Abbott Others Source: Company data The Diagnostic Specialist March 2010 15
Slide 17: Murex is key to DiaSorin's success in HIV and HEP
Murex is key to DiaSorin’s success in HIV and HEP 1. Current know-how and reputation of Murex in the field of HCV and HIV will allow DiaSorin to leverage on a strong brand. 2. Integration of current sales of Murex in South America and Asia/Pacific will allow us to increase our critical mass in those
Slide 18: Murex business – Key financials
Murex business – Key financials Murex turnover ACT 09 (Dec-Nov): USD 66.7 mn (including instrument sales): ● Murex turnover EST 10 (Dec- Nov): USD 60-65 mn ● Expected consolidated sales FY 10: USD ~ 30 mn (€ ~ 21 mn). Murex will be accretive as of year 1. We expect: ● EbITDA margin between 15-19% ●
Slide 19: Diversifying Geographical Focus
Diversifying Geographical Focus Eu&A: € 161.0 mn (52.9%) --------------------------- Eu&A: € 173.3 mn (49.3%) NA: € 101.9 mn APa&C: € 22.6 mn (33.5%) (7.4%) ----------------------- --------------------------- NA: € 101.9 mn APa&C: € 35.7 mn (29.0%) (10.2%) LatAm: € 18.7 mn (6.1%) -------------------